Oncology Institute (TOI) to Release Earnings on Wednesday

Key Points

• Oncology Institute is set to announce its Q2 2025 earnings on August 13th, with analysts predicting earnings of ($0.13) per share and revenue of $112.56 million.
• Insider selling has been notable, with Director Brad Hively selling nearly 2 million shares, representing a 76.61% decrease in his ownership.
• Goldman Sachs recently acquired a new stake in Oncology Institute, purchasing 115,140 shares, which reflects increasing institutional interest in the stock.

Oncology Institute (NASDAQ:TOI - Get Free Report) is expected to be posting its Q2 2025 quarterly earnings results after the market closes on Wednesday, August 13th. Analysts expect Oncology Institute to post earnings of ($0.13) per share and revenue of $112.56 million for the quarter. Oncology Institute has set its FY 2025 guidance at EPS.

Oncology Institute (NASDAQ:TOI - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.18) earnings per share (EPS) for the quarter. Oncology Institute had a negative return on equity of 445.02% and a negative net margin of 15.38%. The company had revenue of $104.41 million for the quarter.

Oncology Institute Stock Up 2.9%

Oncology Institute stock traded up $0.12 during midday trading on Friday, reaching $4.28. The stock had a trading volume of 1,769,661 shares, compared to its average volume of 2,216,191. The company has a fifty day moving average price of $3.00 and a two-hundred day moving average price of $2.11. Oncology Institute has a 12 month low of $0.13 and a 12 month high of $4.50. The company has a current ratio of 1.79, a quick ratio of 1.59 and a debt-to-equity ratio of 14.58. The company has a market capitalization of $381.90 million, a P/E ratio of -6.11 and a beta of 0.08.

Analysts Set New Price Targets

A number of research analysts have weighed in on TOI shares. BTIG Research began coverage on shares of Oncology Institute in a research note on Thursday, May 15th. They issued a "buy" rating and a $7.00 target price on the stock. B. Riley started coverage on Oncology Institute in a research note on Wednesday, July 16th. They set a "buy" rating and a $6.00 price target for the company. Finally, Noble Financial started coverage on Oncology Institute in a report on Wednesday, July 23rd. They issued an "outperform" rating and a $8.00 price objective for the company.

Insiders Place Their Bets

In related news, Director Growth I. L.P. M33 sold 76,324 shares of the stock in a transaction that occurred on Thursday, June 5th. The shares were sold at an average price of $3.05, for a total transaction of $232,788.20. Following the transaction, the director owned 1,272,724 shares in the company, valued at $3,881,808.20. This represents a 5.66% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Brad Hively sold 1,976,137 shares of the stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $2.87, for a total value of $5,671,513.19. Following the transaction, the director directly owned 603,501 shares in the company, valued at $1,732,047.87. The trade was a 76.61% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 4,726,137 shares of company stock valued at $13,379,013. Corporate insiders own 8.50% of the company's stock.

Hedge Funds Weigh In On Oncology Institute

Large investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC grew its position in shares of Oncology Institute by 231.7% during the second quarter. Geode Capital Management LLC now owns 1,279,443 shares of the company's stock valued at $2,623,000 after purchasing an additional 893,696 shares in the last quarter. Goldman Sachs Group Inc. purchased a new stake in shares of Oncology Institute during the 1st quarter worth approximately $131,000. Finally, Cetera Investment Advisers raised its holdings in shares of Oncology Institute by 35.0% during the 2nd quarter. Cetera Investment Advisers now owns 17,545 shares of the company's stock worth $36,000 after acquiring an additional 4,545 shares in the last quarter. Hedge funds and other institutional investors own 36.86% of the company's stock.

Oncology Institute Company Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.